Illumina, Inc.
(NASDAQ : ILMN)

( )
ILMN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.15%454.600.0%$6127.57m
BNTXBioNTech SE 4.05%352.990.0%$1059.79m
NVAXNovavax, Inc. 10.90%257.3079.4%$994.94m
SNSSSunesis Pharmaceuticals, Inc. 2.00%8.690.7%$607.46m
AMGNAmgen, Inc. 0.66%215.051.4%$556.80m
GILDGilead Sciences, Inc. 0.43%71.691.0%$457.92m
REGNRegeneron Pharmaceuticals, Inc. -0.09%646.512.7%$422.03m
TECHBio-Techne Corp. 0.73%536.904.5%$370.97m
ILMNIllumina, Inc. -0.32%433.203.5%$350.21m
BIIBBiogen, Inc. 1.34%293.201.7%$310.59m
VRTXVertex Pharmaceuticals, Inc. 0.45%185.091.9%$247.51m
ISEEIVERIC bio, Inc. 1.44%16.230.0%$190.62m
LIFEaTyr Pharma, Inc. 8.33%12.482.1%$188.70m
DVAXDynavax Technologies Corp. 4.31%19.605.7%$160.10m
BGNEBeiGene Ltd. -0.71%385.421.3%$145.35m

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.